NO20043009L - Substituerte imidazolidiner, fremgangsmate for fremstilling derav, deres anvendelse som et legemiddel eller for diagnose og legemiddel inneholdende substituerte imidazolidiner - Google Patents

Substituerte imidazolidiner, fremgangsmate for fremstilling derav, deres anvendelse som et legemiddel eller for diagnose og legemiddel inneholdende substituerte imidazolidiner

Info

Publication number
NO20043009L
NO20043009L NO20043009A NO20043009A NO20043009L NO 20043009 L NO20043009 L NO 20043009L NO 20043009 A NO20043009 A NO 20043009A NO 20043009 A NO20043009 A NO 20043009A NO 20043009 L NO20043009 L NO 20043009L
Authority
NO
Norway
Prior art keywords
medicament
substituted imidazolidines
diagnosis
preparation
imidazolidines
Prior art date
Application number
NO20043009A
Other languages
English (en)
Norwegian (no)
Inventor
Klaus Wirth
Hans-Jochen Lang
Armin Hofmeister
Uwe Heinelt
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20043009L publication Critical patent/NO20043009L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20043009A 2001-12-21 2004-07-15 Substituerte imidazolidiner, fremgangsmate for fremstilling derav, deres anvendelse som et legemiddel eller for diagnose og legemiddel inneholdende substituerte imidazolidiner NO20043009L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10163239A DE10163239A1 (de) 2001-12-21 2001-12-21 Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament
PCT/EP2002/013921 WO2003053434A1 (de) 2001-12-21 2002-12-09 Substituierte imidazolidine, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie enthaltendes medikament

Publications (1)

Publication Number Publication Date
NO20043009L true NO20043009L (no) 2004-07-15

Family

ID=7710363

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043009A NO20043009L (no) 2001-12-21 2004-07-15 Substituerte imidazolidiner, fremgangsmate for fremstilling derav, deres anvendelse som et legemiddel eller for diagnose og legemiddel inneholdende substituerte imidazolidiner

Country Status (27)

Country Link
EP (1) EP1461034B1 (sr)
JP (1) JP4571803B2 (sr)
KR (1) KR100959031B1 (sr)
CN (1) CN100339079C (sr)
AR (1) AR037932A1 (sr)
AT (1) ATE345797T1 (sr)
AU (1) AU2002361990B2 (sr)
BR (1) BR0215154A (sr)
CA (1) CA2470856A1 (sr)
CO (1) CO5590925A2 (sr)
DE (2) DE10163239A1 (sr)
DK (1) DK1461034T3 (sr)
ES (1) ES2275945T3 (sr)
HR (1) HRP20040573A2 (sr)
HU (1) HUP0600836A2 (sr)
IL (2) IL162562A0 (sr)
MA (1) MA27149A1 (sr)
MX (1) MXPA04005388A (sr)
MY (1) MY134344A (sr)
NO (1) NO20043009L (sr)
PE (1) PE20030741A1 (sr)
PL (1) PL368940A1 (sr)
RS (1) RS53204A (sr)
RU (1) RU2004122415A (sr)
TW (1) TW200305408A (sr)
WO (1) WO2003053434A1 (sr)
ZA (1) ZA200404149B (sr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10323701A1 (de) 2003-05-22 2004-12-23 Aventis Pharma Deutschland Gmbh Verfahren zur Synthese heterocyclischer Verbindungen
EP1640361B9 (en) 2003-06-30 2015-11-04 Sumitomo Chemical Company, Limited Asymmetric urea compounds and process for producing asymmetric compounds by asymmetric conjugate addition reaction using the same as catalyst
DE10341240A1 (de) * 2003-09-08 2005-04-07 Aventis Pharma Deutschland Gmbh Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
ME03311B (me) 2014-07-25 2019-10-20 Taisho Pharmaceutical Co Ltd Fenil teтrahidroizokvinolinsko jedinjenje supsтituisano heteroarilom

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3190802A (en) * 1961-10-09 1965-06-22 Boehringer Sohn Ingelheim Shaving composition and method of using same
US3236857A (en) * 1961-10-09 1966-02-22 Boehringer Sohn Ingelheim 2-(phenyl-amino)-1, 3-diazacyclopentene-(2) substitution products
EP0070084A3 (en) * 1981-04-24 1983-02-16 Beecham Group Plc Imidazoline derivatives
DE3712385A1 (de) * 1987-04-11 1988-10-27 Boehringer Ingelheim Kg 2-(phenylimino)imidazolidine
GB9313330D0 (en) * 1993-06-28 1993-08-11 Fujisawa Pharmaceutical Co New compound and its preparation
EP0639573A1 (de) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
DE4328869A1 (de) * 1993-08-27 1995-03-02 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
KR100257129B1 (ko) * 1993-09-11 2000-05-15 성재갑 신규 세팔로스포린계 항생제 및 이의 제조방법
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
DE19548812A1 (de) * 1995-12-27 1997-07-03 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation
DE19633966A1 (de) * 1996-08-22 1998-02-26 Hoechst Ag Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
ATE244717T1 (de) * 1997-03-14 2003-07-15 Vertex Pharma Inhibitoren des impdh-enzyms
DE19945302A1 (de) * 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenylderivate als NHE-3-Inhibitoren
DE19950898A1 (de) * 1999-10-22 2001-04-26 Aventis Pharma Gmbh Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19960204A1 (de) * 1999-12-14 2001-06-28 Aventis Pharma Gmbh Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10015248A1 (de) * 2000-03-28 2001-10-04 Merck Patent Gmbh Bisamidino-Verbindungen als NHE-3 Inhibitoren
DE10019062A1 (de) * 2000-04-18 2001-10-25 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren
DE10060292A1 (de) * 2000-12-05 2002-06-20 Aventis Pharma Gmbh Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament

Also Published As

Publication number Publication date
IL162562A0 (en) 2005-11-20
CO5590925A2 (es) 2005-12-30
MXPA04005388A (es) 2004-10-11
PE20030741A1 (es) 2003-09-29
HUP0600836A2 (en) 2008-04-28
HRP20040573A2 (en) 2004-10-31
JP2005516947A (ja) 2005-06-09
AU2002361990A1 (en) 2003-07-09
MY134344A (en) 2007-12-31
EP1461034B1 (de) 2006-11-22
RS53204A (sr) 2006-10-27
KR20040068322A (ko) 2004-07-30
DK1461034T3 (da) 2007-03-26
MA27149A1 (fr) 2005-01-03
TW200305408A (en) 2003-11-01
WO2003053434A1 (de) 2003-07-03
PL368940A1 (en) 2005-04-04
CN100339079C (zh) 2007-09-26
BR0215154A (pt) 2004-10-19
IL162562A (en) 2009-12-24
KR100959031B1 (ko) 2010-05-20
DE10163239A1 (de) 2003-07-10
DE50208809D1 (de) 2007-01-04
AU2002361990B2 (en) 2008-10-09
RU2004122415A (ru) 2005-03-27
ZA200404149B (en) 2006-05-31
ATE345797T1 (de) 2006-12-15
AR037932A1 (es) 2004-12-22
CA2470856A1 (en) 2003-07-03
CN1606440A (zh) 2005-04-13
EP1461034A1 (de) 2004-09-29
ES2275945T3 (es) 2007-06-16
JP4571803B2 (ja) 2010-10-27

Similar Documents

Publication Publication Date Title
NO20035298D0 (no) CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
NO20040356L (no) Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
NO20033726D0 (no) Xantin-derivater, fremstilling og anvendelse derav som et medikament
DK1445252T3 (da) Sulfonamid-derivater, deres fremstilling og anvendelse som medikamenter
DK1549341T3 (da) Mod vævsfaktor rettede antistoffer som antikoagulanter
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
DK1095025T3 (da) Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
NO20031273L (no) Substituerte kanelsyreguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som legemiddel og legemiddel som inneholder de samme
ITMI20020622A0 (it) Perno di fissaggio per membrana di rigenerazione di tessuti dentali
NO20025879L (no) Acylfenylureaderivater, fremgangsmåter for fremstilling derav og deres anvendelse som legemiddel
NO20011503D0 (no) Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, deres fremstilling og anvendelse som anorektiske legemidler
NO20041785L (no) Farmasoytisk sammensetning som innbefatter mykofenolsyre eller mykofenolatsalt
NO20042635L (no) 5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin
NO20044322L (no) Benzoksanon-avledede forbindelser, deres fremstilling og anvendelse som medikament
NO20035450D0 (no) Antranilsyreamider med en heteroarylsulfonyl sidekjede, fremgangsmåte for fremstilling derav, anvendelse som et legemiddel eller diagnostiske-og farmas degree ytiske preparater som inneholder nevnte forbindelser
NO20005146D0 (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
DK1322158T3 (da) Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
NO20040860L (no) Farmasoytisk sammensetning som innbefatter lumiracoxib
NO20040210L (no) Fenylacetamido-tiazolderivater, fremgangsmate for deres fremstilling og deres anvendelse som antitumormidler
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
NO20022801D0 (no) Substituerte norbornylaminoderivater, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikumsåvel som medikamenter inneholdende disse
NO20045504L (no) Substituerte tiofener, fremgangsmate for fremstilling, deres anvendelse som medikament eller diagnostisk middel samt et medikament inneholdende disse
NO20043009L (no) Substituerte imidazolidiner, fremgangsmate for fremstilling derav, deres anvendelse som et legemiddel eller for diagnose og legemiddel inneholdende substituerte imidazolidiner
ITMI20021771A1 (it) Uso di soluzioni attive per la disinfezione e/o sterilizzazione di un riunito dentale e relativo metodo.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application